• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Type II diabetes associated with decreased survival in pancreatic cancer

byMonica ParksandDavid Wang
November 30, 2014
in Chronic Disease, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Long-standing type II diabetes mellitus in patients with pancreatic cancer is associated with decreased survival compared to non-diabetics.

2. No differences in survival were observed in patients with recent onset diabetes (<4 years prior to cancer diagnosis).

Evidence Rating Level: 3 (Average)

Study Rundown: Pancreatic cancer is the fourth leading cause of cancer mortality in the United States with a median survival of <12 months post-diagnosis. Type II diabetes mellitus (T2DM) is associated with a number of systemic metabolic and inflammatory changes, and has been observed to contribute both as a risk factor for the development of pancreatic cancer as well as a clinical marker of sub-clinical pancreatic cancer. However, the relationship between T2DM and pancreatic cancer survival is not well established. The purpose of this study was to evaluate the impact of long-standing T2DM on overall pancreatic cancer survival.

The study analyzed pancreatic cancer survival stratified by T2DM status from 2 large prospective community patient databases and a third ongoing, clinic-based database. Overall, over 1300 pancreatic patients were included in the analysis. At the conclusion of the study, the authors found that long-standing T2DM, defined as diagnosis 4 years or more prior to the diagnosis of cancer, was associated with decreased survival compared to non-diabetic patients. The effect remained significant after adjustments for confounders and co-morbid conditions. However, recent onset T2DM (diagnosis less than 4 years prior to cancer), did not demonstrate a significant decrease in survival. The study was strengthened by its the large sample size and the use of prospective population cohorts, which captured a large spectrum of patients with varying degrees of disease aggressiveness. The results of this study support the use of long-standing T2DM as a prognostic factor in pancreatic cancer. However, it should be noted that the population cohort was primarily composed of patients of European descent which may reduce the generalizability to other patient populations.

Click to read the study in Journal of Clinical Oncology

Relevant Reading: Type II diabetes and pancreatic cancer: a meta-analysis of 36 studies

RELATED REPORTS

Faricimab may improve visual acuity in patients with diabetic macular edema

Supplementation of tirzepatide for type 2 diabetics on basal insulin improved glycemic control compared to placebo

Neoadjuvant chemoradiotherapy demonstrates a long-term survival benefit in pancreatic cancer patients when compared to upfront surgery

In-Depth [prospective cohort]: This study collected data from 3 prospective cohort studies, the Nurses’ Health Study (NHS), the Health Professionals Follow-Up Study (HPFS), and a third ongoing prospective clinic-based case series. Eligible patients had pathologically confirmed pancreatic adenocarcinoma; a total of 635, 371, and 386 pancreatic cancer patients were enrolled from each of these studies, respectively. In all 3 studies, over 90% of the patient population self-identified as white. In the NHS and HPFS studies, patients with long-term T2DM demonstrated a 40-50% reduction in overall survival compared to non-diabetics (median survival times of 3 months for T2DM compared to 5 months for non-diabetics); the HR for overall mortality was 1.40 (95% CI: 1.15-1.69, p<0.001). The result remained significant after adjustments for propensity scores for varying difference in comorbidities (HR: 1.46; 95% CI: 1.17-1.80, p<0.001). In the prospective clinic-based trial, a similar survival reduction were seen among patients with T2DM (9 months versus 13 months in non-diabetics) with a HR of 1.53 (95% CI: 1.07-2.20, p=0.02). There was no statistically significant association of recent onset T2DM (diagnosis <4 years) with survival vs non-diabetics (HR: 1.12; 95% CI: 0.90-1.39).

More from this author: Rituximab linked with reduced chronic immune disease following stem cell transplantation, High-dose prophylaxis for hemophilia increases costs with minimal benefit, Ambrisentan found ineffective against idiopathic pulmonary fibrosis

Image: PD

©2014 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. No article should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2 Minute Medicine, Inc.

Tags: pancreatic cancerType 2 Diabetes Mellitus
Previous Post

Shear-wave elastography may improve prostate cancer detection

Next Post

Culture characteristics not associated with birthweight from assisted reproduction

RelatedReports

Blindness and visual impairment decreasing worldwide
Chronic Disease

Faricimab may improve visual acuity in patients with diabetic macular edema

March 8, 2022
Insulin costs rose exponentially, regardless of formulation or patent
Cardiology

Supplementation of tirzepatide for type 2 diabetics on basal insulin improved glycemic control compared to placebo

February 9, 2022
Rectal indomethacin dose escalation for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography in high-risk patients
Oncology

Neoadjuvant chemoradiotherapy demonstrates a long-term survival benefit in pancreatic cancer patients when compared to upfront surgery

March 27, 2022
Cardiology

Tirzepatide is superior to insulin glargine for management of type 2 diabetes and elevated cardiovascular risk

January 11, 2022
Next Post
Assisted conception not associated with increased pediatric cancer risk

Culture characteristics not associated with birthweight from assisted reproduction

Obstetric scoring systems overestimate cases of severe sepsis

Obstetric scoring systems overestimate cases of severe sepsis

AAP highlights pediatricians’ play role in improving oral health

AAP highlights pediatricians’ play role in improving oral health

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Wellness Check: Mental Health
  • #VisualAbstract: Addition of elotuzumab to lenalidomide and dexamethasone did not significantly improve survival outcomes in newly diagnosed, transplant-ineligible multiple myeloma
  • #VisualAbstract: Pretreatment with radiotherapy and two cycles of concurrent cisplatin may reduce toxicity in locally advanced nasopharyngeal carcinoma
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.